Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Acquisitions & Divestments (2022 - 2025)

Historic Change in Acquisitions & Divestments for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $75.5 million.

  • Entrada Therapeutics' Change in Acquisitions & Divestments fell 936.44% to $75.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.6 million, marking a year-over-year decrease of 1799.61%. This contributed to the annual value of $413.1 million for FY2024, which is 5052.4% up from last year.
  • Per Entrada Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $75.5 million for Q3 2025, which was down 936.44% from $50.6 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $123.9 million for Q1 2024, and its period low was $1.7 million during Q1 2022.
  • Moreover, its 4-year median value for Change in Acquisitions & Divestments was $74.5 million (2023), whereas its average is $65.1 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first surged by 357561.26% in 2023, then tumbled by 4204.57% in 2025.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Change in Acquisitions & Divestments stood at $19.5 million in 2022, then skyrocketed by 456.62% to $108.5 million in 2023, then rose by 9.17% to $118.5 million in 2024, then plummeted by 36.28% to $75.5 million in 2025.
  • Its last three reported values are $75.5 million in Q3 2025, $50.6 million for Q2 2025, and $85.9 million during Q1 2025.